<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="rapid-communication"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Curr</journal-id><journal-title-group><journal-title>PLoS Currents</journal-title></journal-title-group><issn pub-type="epub">2157-3999</issn><publisher><publisher-name>Public Library of Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">20029604</article-id><article-id pub-id-type="pmc">2762331</article-id><article-id pub-id-type="knolid">http://knol.google.com/k/-/-/1uji2pldf66z5/1</article-id><article-id pub-id-type="accession">PMC2762331</article-id><article-id pub-id-type="doi">10.1371/currents.RRN1007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Influenza</subject></subj-group></article-categories><title-group><article-title>Predispensing of Antivirals to High-Risk Individuals in an Influenza Pandemic</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Goldstein</surname><given-names>Edward</given-names></name><!--Senior Research Scientist--></contrib><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Joel C.</given-names></name><!--Scientist--></contrib><contrib contrib-type="author"><name><surname>O'Hagan</surname><given-names>Justin</given-names></name><!--Doctoral Student, Boston--></contrib><contrib contrib-type="author"><name><surname>Lipsitch</surname><given-names>Marc</given-names></name></contrib></contrib-group><aff>Harvard School of Public Health</aff><pub-date pub-type="epub"><day>12</day><month>11</month><year>2009</year></pub-date><volume>1</volume><elocation-id>RRN1007</elocation-id><history><date date-type="created"><day>17</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>20</day><month>8</month><year>2009</year></date></history><permissions><license><license-p>This research note is distributed under the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">Creative Commons
						Attribution 3.0 License.</ext-link></license-p></license></permissions><abstract><!--WRITE-PARA--><p id="p1">We consider the net benefits of predispensing antivirals to high-risk individuals during an
        influenza pandemic, where the measure of the benefit is the number of severe outcomes (such
        as deaths or hospitalizations) prevented by antivirals in the whole population. One
        potential benefit of predispensing is that individuals to whom antivirals have been
        predispensed may be able to initiate treatment earlier than if they had to wait to obtain
        and fill a prescription, reducing their risk of progression to severe disease. If this
        benefit exceeds the side effects of misuse for the category of individuals to whom
        antivirals were predispensed, and if antiviral supply exceeds overall population demand
        (which appears relevant for several countries including US in the current H1N1 pandemic),
        predispensing a quantity of antivirals not exceeding the difference between supply and
        demand is always beneficial. In this paper we consider the net benefits of predispensing
        antivirals under various scenarios, including demand exceeding supply, and derive
        mathematical conditions under which antiviral predispensing is advantageous on balance. For
        individuals whose relative risk of severe outcome is high enough, such as immunosuppressed
        individuals (particularly children) and possibly individuals with neurological disorders,
        predispensing is always beneficial at a given level of antiviral stockpile with modest
        assumptions on the relative benefit of early treatment by a predispensed course, regardless
        of the overall population demand for antivirals during the course of an epidemic. Making
        additional assumptions on either the overall population demand for antivirals (which appear
        relevant in the current situation) or on the relative benefit of predispensing would make
        predispensing net beneficial with inclusion of a larger number of persons such as pregnant
        women and morbidly obese adults.</p></abstract></article-meta></front><body><!--WRITE-PARA--><p id="p2">A key objective for the response to the autumn wave of pandemic influenza A/H1N1 (H1N1pdm) in
      the Northern Hemisphere is to reduce severe morbidity and mortality that would result from an
      unmitigated pandemic.&#x000a0; Broadly, such responses may be divided into two groups: (a)
      efforts to reduce population-wide transmission of the virus and thereby protect individuals
      from becoming infected, either permanently (vaccination) or for a period of time until
      vaccines become widely available (non-pharmaceutical interventions), and (b) efforts to
      protect individuals at particularly high risk of complications from becoming infected or, if
      infected, from developing severe disease.&#x000a0; Here we concentrate on aspect (b) of the
      response via the usage of antiviral drugs.</p><!--WRITE-PARA--><p id="p3">The ability of antiviral drugs to alleviate symptoms and shorten their duration is well
      documented for seasonal influenza, particularly if antivirals are taken during the earlier
      stages of influenza infection <xref ref-type="bibr" rid="ref-3070768605">[1]</xref>
      <xref ref-type="bibr" rid="ref-2509778060">[2]</xref>
      <xref ref-type="bibr" rid="ref-2593680428">[3]</xref>. A 2003 study suggests a 60% reduction in influenza hospitalization rates for
      patients who received early antiviral treatment for seasonal influenza <xref ref-type="bibr" rid="ref-2321005289">[4]</xref>. For H1N1pdm, recent data <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;show that among hospitalized patients, severe outcomes (ICU admission
      and/or death) were less likely in patients who received antiviral treatment within two days of
      symptom onset; the same conclusion is true for lethal outcomes in hospitalized patients in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. </p><!--WRITE-PARA--><p id="p4">Several recent studies suggest that most severe outcomes for H1N1pdm infection occur in
      individuals with pre-existing medical conditions <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
      <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
      <xref ref-type="bibr" rid="ref-316639952">[7]</xref>
      <xref ref-type="bibr" rid="ref-2436736239">[8]</xref>
      <xref ref-type="bibr" rid="ref-1590500135">[9]</xref>
      <xref ref-type="bibr" rid="ref-1504385554">[10]</xref>
      <xref ref-type="bibr" rid="ref-1239612372">[11]</xref>
      <xref ref-type="bibr" rid="ref-166664201">[12]</xref>, though the exact percentages vary between the studies.&#x000a0; This has been
      recognized in several countries, where prompt antiviral prescription to symptomatic high-risk
      individuals is recommended <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>
      <xref ref-type="bibr" rid="ref-3427677528">[14]</xref>
      <xref ref-type="bibr" rid="ref-776221430">[15]</xref>
      <xref ref-type="bibr" rid="ref-2030528610">[16]</xref>
      <xref ref-type="bibr" rid="ref-2242979749">[17]</xref>. However in several countries, including US, such a prescription requires a doctor
      visit. Such a visit may be problematic to symptomatic individuals with underlying health
      conditions and may not occur promptly enough for various reasons, including a possible wait
      for symptoms to go away. Predispensing antiviral drugs so that individuals in high-risk groups
      have access to medications immediately upon becoming symptomatic without the need to seek a
      prescription or fill it in a time of possible scarcity may be a valuable strategy to reduce
      their risk of severe disease or mortality.&#x000a0; Predispensing here is defined as a policy
      (most likely implemented by an individual physician) of prescribing and urging a patient to
      fill the prescription for a course of neuraminidase inhibitor in advance of any known
      infection with H1N1pdm.&#x000a0; The patient would be instructed to begin self-treatment
      (possibly following communication with the physician) upon meeting a definition of a suspected
      H1N1pdm infection. </p><!--WRITE-PARA--><p id="p5">The benefit of using a predispensed course of antivirals vs. one obtained by prescription is
      hard to assess.&#x000a0; However if one believes that such a benefit does exist and exceeds
      the side effects for the category of individuals to whom antivirals were predispensed,
      predispensing of antivirals is always advisable in a situation when the population demand for
      antivirals is smaller than the available supply. &#x000a0;This is because predispensing a
      quantity of antivirals not surpassing the difference between supply and demand would not
      deprive anybody of an antiviral course, and a predispensed course is more likely to prevent a
      severe outcome than a course obtained by prescription during the epidemic. The scenario of
      supply exceeding demand appears relevant to several developed countries with a large supply of
      antivirals, and evidently to the US due to strict current prescription guidelines for low risk
        individuals&#x000a0;<xref ref-type="bibr" rid="ref-3139123044">[13]</xref>.&#x000a0; This simple rationale is perhaps the main practical motivation behind
      antiviral predispensing in a current H1N1 epidemic.</p><!--WRITE-PARA--><p id="p6">In a scenario when demand exceeds supply, there is additional benefit to predispensing having
      to do with the fact that a predispensed course of antivirals would end up in the hands of a
      high-risk rather than a low-risk person, and thus is more likely to prevent a severe
      outcome.&#x000a0; There is also harm to predispensing in this case resulting from the fact
      that some antivirals will be in the hands of individuals who will not need them, and hence
      will be wasted, depriving others who do need them of access.</p><!--WRITE-PARA--><p id="p7">In this paper we examine the net benefits of predispensing antivirals under various
        levels of&#x000a0; population demand.&#x000a0; We define conditions under which
        predispensing a defined quantity of antivirals, one course each to a subpopulation at high
        risk of death or hospitalization from H1N1pdm infection would provide a net benefit in terms
        of reducing severe outcomes compared to a policy of leaving them in state and national
        stockpiles for distribution only to infected patients. At a given level of antiviral supply
        and relative benefit of early treatment there may be some groups of individuals with
        sufficiently high relative risk of dying such that predispensing is always beneficial
        regardless of the overall population demand for antivirals during the course of an
        epidemic.&#x000a0; Under certain assumptions about the overall demand for
        antivirals&#x000a0; -- namely, that it is not too close to the total supply &#x02013; one
        can show that there is a net benefit to predispensing to a larger class of high-risk persons
        (those with risk above the population average, but not in the highest-risk category). We
        will attempt to quantify these situations in the context of limited available data on severe
        outcomes in high-risk individuals.</p><sec id="sec1"><title>
        <bold>Relative risks for certain high-risk groups</bold>
      </title><!--WRITE-PARA--><p id="p8">In this section we attempt to assess relative risks for a severe outcome from H1N1
        infection for certain high-risk groups for which data is available. Our data sources are <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
        <xref ref-type="bibr" rid="ref-2436736239">[8]</xref>
        <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>
        <xref ref-type="bibr" rid="ref-3267758521">[19]</xref>. The estimates below are crude and based on limited available data. Also
        throughout this section, a relative risk for a severe outcome for a high-risk group is the
        ratio of the rate of this severe outcome (per capita) in this high-risk group over the rate
        of that severe outcome in the whole population. </p><!--WRITE-PARA--><p id="p9">Pregnant women constitute 1% of the US population <xref ref-type="bibr" rid="ref-2436736239">[8]</xref>. An estimate in <xref ref-type="bibr" rid="ref-2436736239">[8]</xref>&#x000a0;suggests that they are about 4 times more likely to be hospitalized due
        to H1N1 infection compared to general public. The percentages of pregnant women among
        hospitalized patients in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;and <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;are 6.6% and 9.6% correspondingly.&#x000a0; The percentage of pregnant
        women among deaths in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;is 5.1%; the percentage of pregnant women among deaths or ICU admissions
        in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;is 9%. We therefore estimate the relative risk for hospitalization for
        pregnant women to be between 4-9.6, and the relative risk for death or ICU admission to be
        between 5.1-9.</p><!--WRITE-PARA--><p id="p10">Morbidly obese adults (BMI <inline-formula><tex-math id="d20e171">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$\geq 40$\end{document}</tex-math></inline-formula>) constitute 4.8% of the adult US population <xref ref-type="bibr" rid="ref-3267758521">[19]</xref>, and correspondingly 3.63% of the of the whole US population. Data in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;suggest that morbidly obese adults constitute 18.6% of hospitalized
        cases, and 31.5% of fatal cases.&#x000a0; Data in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;(which has a lower percentage of adults compared to <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>) suggests that 14.3% of hospitalized patients were morbidly obese adults; among
        patients who died or were transferred to ICU, 20.6% were morbidly obese adults.&#x000a0;Thus
        we estimate that the relative risk for hospitalization for morbidly obese adults ranges in
        3.95 &#x02013; 5.11, while the relative risk for ICU admission or death ranges in 5.68
        &#x02013; 8.68. </p><!--WRITE-PARA--><p id="p11">We draw our data on the percentages of immunosuppressed individuals in different age groups
        in the US from <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>&#x000a0;(kindly provided by Diane Wagener). The National Health Interview Survey
        (NHIS), conducted annually by the Centers for Disease Control and Prevention (CDC), was used
        as a principal source for prevalence data in <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>. Specific sources are: Cancer in past 3 years 2006 data (National Health
        Interview Survey, 2006); HIV/AIDS 2006 data CDC Surveillance, 2007 Report <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2007report/default.htm">http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2007report/default.htm</ext-link>;
        ESRD (US Renal Data System, Table D.11); Transplants data (Organ procurement and
        Transplantation Network, 2009).</p><!--WRITE-PARA--><p id="p12">Immunosuppression is very rare in children, accounting for less than 0.18% of the
        population of children, thus less than 0.044% in the overall population <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>. At the same time, immunocompromised children represent 6.4% of all H1N1-related
        hospitalizations in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref> and 5.3% of all H1N1-related hospitalizations in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. They also represent 3/118 (2.5%) of all deaths in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. Thus we estimate the relative risk for hospitalization to be between 120-145,
        and the relative risk for death to be 57. Another way to look at those numbers is to note
        that there are around 130,000 immunocompromised children in the US. There were 17838
        laboratory-confirmed influenza associated hospitalizations in the US between August 30 and
        October 31 <xref ref-type="bibr" rid="ref-2562081569">[20]</xref>. Assuming a total of 30000 H1N1pdm-associated influenza hospitalizations in the
        US and the percentages of immunocompromised children among the hospitalized from <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
        <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>, we get that roughly 1 in 75 immunocompromised children is hospitalized with H1N1
        in the US. </p><!--WRITE-PARA--><p id="p13">Immunocompromised adults represent 1.9% of the US population <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>. They represent 10.2% of all hospitalizations and 30.5% of all fatalities in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. Immunocompromised adults represent 10.7% of hospitalizations in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>. Immunocompromised individuals represent 17.9% of all deaths or ICU admissions in
          <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>; presumably most of them are adults. Thus we estimate the relative risk for
        hospitalization for immunocompromised adults to be between 5.4 &#x02013; 5.6, and their
        relative risk for death between 9.4 &#x02013; 16.1.</p><!--WRITE-PARA--><p id="p14">We have no data on prevalence of individuals with neurological (neurocognitive and
        neuromuscular) disorders.&#x000a0; At the same time, children with neurological disorders
        represent 9.9% of all hospitalizations in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>. Children with neuromuscular disorders represent 4.5% of all hospitalizations,
        and 3.4% of all deaths in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. Moreover children with neurological disorders have an increased relative risk
        for respiratory failure given hospitalization <xref ref-type="bibr" rid="ref-1047776214">[21]</xref>. Adults with neuromuscular disorders represent 11.9% of all deaths in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>.&#x000a0; People with neurocognitive or neuromuscular disorders each represent
        13.4% of deaths or ICU admissions in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>.</p></sec><sec id="sec2"><title>
      
        <bold>Benefits and harms of predispensing</bold>
      </title><!--WRITE-PARA--><p id="p15">To fix notation, we assume here that we seek to optimize the number of lives saved (i.e.
        minimize the number of lives lost due to H1N1pdm); however, with suitable modifications to
        the definitions of all terms, we could equally attempt to prevent hospitalizations or
        intensive care admissions.&#x000a0;&#x000a0; There are at least two possible benefits, and
        three harms, to predispensing.&#x000a0; The first benefit of predispensing is that a patient
        possessing a predispensed course of antivirals will likely begin therapy earlier in the
        course of H1N1pdm infection than one must acquire a prescription (possibly including a visit
        to a physician) and fill it, thereby most likely delaying treatment.&#x000a0; This benefit
        accrues whether or not there is a shortage of antivirals, since it simply reflects the time
        required to acquire and fill the prescription.&#x000a0; A second possible benefit occurs if
        the demand for antivirals exceeds supply, so that not all patients who attempt to acquire
        antivirals can do so.&#x000a0; In this situation, predispensing a course assures that it is
        in the hands of someone who, if untreated, would be likely to develop severe disease, rather
        than (potentially) going to someone who will not likely develop severe disease, and whose
        benefit from taking the antiviral would therefore be less.&#x000a0;</p><!--WRITE-PARA--><p id="p16">The first harm of predispensing occurs only if total demand for antivirals exceeds supply,
        namely, a predispensed course is unavailable to anyone who may need it other than the person
        who has received it.&#x000a0; If demand exceeds supply, this means one more person, possibly
        someone who would benefit greatly from having the antiviral is unable to obtain it.&#x000a0;
        A second harm of predispensing is the possibility that a predispensed course will be used by
        a high-risk individual who would not otherwise be able to obtain an antiviral drug, and this
        usage will lead to a severe side effect.&#x000a0; We have no way of assessing the likelihood
        of such an outcome; in particular, the major severe side effects reported to date are
        neuropsychiatric events in oseltamivir recipients, and the manufacturer&#x02019;s data
        review concludes that there is no evidence of a causal link between oseltamivir and these
        adverse events <xref ref-type="bibr" rid="ref-374826205">[22]</xref>. &#x000a0;We will not model this second harm in our analysis. Yet another
        possible harm to predispensing is preliminary evidence that people treated with antivirals
        have lower levels of antibodies compared to people who weren&#x02019;t. We are not aware of
        data quantifying additional risk for re-infection, if any, after antiviral treatment
        compared to no antiviral treatment. Therefore we will not model this potential harm
        either.</p><!--WRITE-PARA--><p id="p17">To assess the net benefit or harm from predispensing, we define some notation, summarized
        in Table 1.&#x000a0; We divide the total population into two groups: a <italic>high-risk
          group</italic> for which we are considering predispensing, and <italic>the general population</italic>,
        which is comprised of all individuals not in the high-risk group.&#x000a0; These constitute
        respectively a proportion <inline-formula><tex-math id="d20e275">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; (high risk) and &#x000a0;<inline-formula><tex-math id="d20e280">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}1-q\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; (general population) of the total population.&#x000a0; Within the
        general population, risks may vary, so some individuals may be at higher risk than
        others.&#x000a0;&#x000a0; To keep the exposition simple we assume throughout that under
        predispensing, all <inline-formula><tex-math id="d20e285">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula> members of the high-risk group receive the predispensed drug; the sufficient
        conditions for predispensing to be beneficial still hold if uptake is less than perfect, as
        it will be in practice.&#x000a0; All quantities in our notation are defined as proportion of
        the total population, hence lie between 0 and 1.&#x000a0; Let <italic>T</italic> be the total supply
        of antivirals (as a proportion of the population); thus, if enough antivirals are available
        for treatment of 20% of the population, then <italic>T</italic>=0.2 .&#x000a0; Let <italic>D</italic> be the
        demand for antivirals in the general population, that is the number of individuals not at
        high risk who would receive antiviral treatment in the general population if supply were not
        limited; in practice, some of this demand may be unmet as the supply is
        constrained.&#x000a0; Let <inline-formula><tex-math id="d20e300">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_d\end{equation*}\end{document}</tex-math></inline-formula> be the probability of dying from the infection over the whole course of the
        epidemic in the whole population (if no antivirals are used); the death probability in a
        high risk group is&#x000a0;<inline-formula><tex-math id="d20e305">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}Rp_d\end{equation*}\end{document}</tex-math></inline-formula> .&#x000a0; Note that these death probabilities are not conditional on infection
        (i.e., are not case-fatality proportions) but are unconditional, reflecting the risk of
        infection times the risk of dying from infection.&#x000a0; Here the number <inline-formula><tex-math id="d20e310">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;is the relative risk of dying in a high risk group compared to the
        general population.&#x000a0; <inline-formula><tex-math id="d20e316">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula> can be estimated from the existing epidemic data while&#x000a0;<inline-formula><tex-math id="d20e321">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_d\end{equation*}\end{document}</tex-math></inline-formula> may be hard to estimate a priori; as we shall see, <inline-formula><tex-math id="d20e326">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_d\end{equation*}\end{document}</tex-math></inline-formula> is factored out of our equations and need not be known.
          &#x000a0;&#x000a0;Let&#x000a0;<inline-formula><tex-math id="d20e331">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_S\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; be the probability that a course of antivirals obtained from a stockpile
        during the epidemic would save a life of a person who would die otherwise.&#x000a0; We
        assume that this probability is the same between high-risk individuals and members of the
        general population.&#x000a0; This key assumption may be incorrect, and is discussed
        later.&#x000a0; Let&#x000a0;<inline-formula><tex-math id="d20e336">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}Bp_s\end{equation*}\end{document}</tex-math></inline-formula> be the probability that a predispensed course of antivirals would save a life of
        a high risk person who would die otherwise.&#x000a0;&#x000a0;<inline-formula><tex-math id="d20e341">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; can be thought of as&#x000a0; the &#x0201c;relative benefit&#x0201d; in
        preventing mortality of receiving a predispensed course of antivirals for a high risk person
        who takes it, compared to receiving a non-predispensed course. <inline-formula><tex-math id="d20e347">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; captures the benefit of early vs. delayed treatment; however, <inline-formula><tex-math id="d20e352">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; also may be reduced to the extent that a predispensed course is taken
        for non-influenza illness, in which case it cannot save a life.&#x000a0; Thus <inline-formula><tex-math id="d20e357">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; exceeds one to the extent that early treatment is better than delayed
        treatment, but it is decremented in proportion to the probability that the course is wasted
        before it is needed. </p><!--WRITE-PARA--><p id="p18">Let&#x000a0; <inline-formula><tex-math id="d20e364">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;be the total number of people in the general population who would die
        during the epidemic and whose lives would be saved if they received antivirals upon demand
        during the course of the epidemic. &#x000a0;Since the total number of people in the
        total&#x000a0; population who would die during the epidemic and whose lives would be saved
        if they received antivirals during the course of the epidemic is&#x000a0;<inline-formula><tex-math id="d20e369">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_dp_s\end{equation*}\end{document}</tex-math></inline-formula> , clearly&#x000a0;<inline-formula><tex-math id="d20e374">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\leq p_dp_s\end{equation*}\end{document}</tex-math></inline-formula> .&#x000a0; We make additional assumptions about how the probability of receiving
        antivirals behaves if demand exceeds supply; these are made explicit in Appendix A. </p><!--WRITE-PARA--><p id="p19">TABLE 1: Parameters of the model, as a proportion of the total population (including
        high-risk and general populations)</p><table-wrap id="d20e381"><table width="446" border="1" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <bold>Parameter </bold>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">
                <bold>Definition</bold>
              </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e400">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T\end{equation*}\end{document}</tex-math></inline-formula>
                &#x02028;
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Supply of antivirals, before predispensing, as a fraction of total population
                size</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e414">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D,D'\end{equation*}\end{document}</tex-math></inline-formula>
                &#x02028;
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Number of antiviral courses used by the general population (&#x000a0;<inline-formula><tex-math id="d20e424">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\end{equation*}\end{document}</tex-math></inline-formula> ) or total population (&#x000a0;<inline-formula><tex-math id="d20e429">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D'\end{equation*}\end{document}</tex-math></inline-formula> ) if no supply constraint, as fraction of the total population size </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e438">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\end{equation*}\end{document}</tex-math></inline-formula>
                &#x02028;
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Total number of lives in the general population that would be saved under no
                predispensing, if no supply constraint</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e452">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Proportion of persons in the high risk group to whom predispensing of one course is
                considered, hence also the number of courses considered for predispensing, as a
                fraction of the total population</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e464">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_s\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Probability that a course of antivirals obtained during the epidemic would save a
                life of a person who would die otherwise, absent any predispensing</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e476">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Relative benefit (in terms of probability of saving life) for a high risk person to
                be treated early (with a predispensed course) compared to being treated with a
                non-predispensed course. Thus <inline-formula><tex-math id="d20e484">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_SB\end{equation*}\end{document}</tex-math></inline-formula> is the probability that a predispensed course of antivirals would save a
                life of a high risk person who would die otherwise </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e493">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_d\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Death rate from the epidemic in the whole population, if no antivirals were
                used</td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:80.45pt">
                <inline-formula><tex-math id="d20e505">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:365.95pt">Ratio between the death rate in the high risk group and the general population.</td></tr></tbody></table></table-wrap><!--WRITE-PARA--><p id="p39">With this notation in place, we can define the conditions under which it is advantageous to
        predispense 1 course each to a proportion <inline-formula><tex-math id="d20e519">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;of the population.&#x000a0; Our main result is the following: </p><!--WRITE-PARA--><p id="p41">MAIN RESULT: Predispensing saves more lives than not predispensing when any of the
        following conditions hold:</p><!--WRITE-PARA--><p id="p43">
        (i)&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Supply of antivirals exceeds
        demand even after predispensing, and&#x000a0;<inline-formula><tex-math id="d20e533">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e;1\end{equation*}\end{document}</tex-math></inline-formula> . </p><!--WRITE-PARA--><p id="p44"> (ii)&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Demand <inline-formula><tex-math id="d20e540">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;in the general population exceeds supply even without predispensing, and
        the following conditions are met:&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; </p><!--WRITE-PARA--><p id="p45">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
          <inline-formula><tex-math id="d20e547">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e; \frac{T}{D}\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;and&#x000a0; <inline-formula><tex-math id="d20e552">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R&#x0003e;\frac{1}{D(B-T/D)}\end{equation*}\end{document}</tex-math></inline-formula>
      </p><!--WRITE-PARA--><p id="p46"> (iii)&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Supply
        exceeds demand without predispensing, but after predispensing, demand exceeds
          supply,<inline-formula><tex-math id="d20e559">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$(T-q\leq D\leq T)$\end{document}</tex-math></inline-formula> and the following conditions are
        met:&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0;&#x000a0;&#x000a0; </p><!--WRITE-PARA--><p id="p47"> &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0; &#x000a0;
        &#x000a0; &#x000a0; &#x000a0; &#x000a0;&#x000a0; <inline-formula><tex-math id="d20e566">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e; \frac{T}{D}\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; and&#x000a0;&#x000a0;&#x000a0; <inline-formula><tex-math id="d20e571">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R&#x0003e;\frac{D+q-T}{Dq(B-1)}\end{equation*}\end{document}</tex-math></inline-formula>. </p><!--WRITE-PARA--><p id="p48">(iv)&#x000a0;&#x000a0;&#x000a0; The above results show that even if demand cannot be
        predicted, predispensing is advantageous when</p><!--WRITE-PARA--><p id="p49">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
          <inline-formula><tex-math id="d20e580">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e;1\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; and&#x000a0; &#x000a0;&#x000a0;&#x000a0; <inline-formula><tex-math id="d20e585">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R&#x0003e;\frac{1}{T(B-1)}\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; &#x02028;
      </p><!--WRITE-PARA--><p id="p51">The justification of this result and the assumptions underlying it are presented in
        Appendix B.&#x000a0; Condition (iv) tells us when a group is at high enough risk that it is
        worth predispensing to them even if we have no idea of the expected antiviral demand.</p><!--WRITE-PARA--><p id="p52">This result can be seen graphically in Figures 1-2, which considers a hypothetical case in
        which there is a supply adequate for&#x000a0;<inline-formula><tex-math id="d20e598">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T=0.2\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; of the population, and predispensing to&#x000a0;<inline-formula><tex-math id="d20e603">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q=3\%\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; of the total population is under consideration.&#x000a0;&#x000a0;The
        parameter that varies between the figures is the relative benefit <inline-formula><tex-math id="d20e608">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;of saving a life by a predispensed course vs. a course obtained by
        prescription. We are not aware of data allowing an assessment of this parameter; we consider
        2 scenarios:&#x000a0;<inline-formula><tex-math id="d20e613">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=2$\end{document}</tex-math></inline-formula>&#x000a0;(Figure 1), <inline-formula><tex-math id="d20e618">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=1.3$\end{document}</tex-math></inline-formula>&#x000a0;(Figure 2). </p><!--WRITE-PARA--><p id="p53"> The far left side of each of the figures shows low levels of demand, in which there is no
        harm to predispensing, so predispensing to any group for which <inline-formula><tex-math id="d20e626">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B&#x0003e;1$\end{document}</tex-math></inline-formula>&#x000a0;may be beneficial.&#x000a0; At the far right, competition for antivirals
        is strong, so all antivirals are used, mostly by the general population, and it is
        beneficial to predispense even to a group that gets modest benefit from antivirals in order
        to capture the benefit of early treatment.&#x000a0; In the middle, when demand is similar to
        supply, it is beneficial to predispense only to groups that benefit disproportionately from
        antivirals (<inline-formula><tex-math id="d20e631">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R&#x0003e;5$\end{document}</tex-math></inline-formula>&#x000a0;for&#x000a0; <inline-formula><tex-math id="d20e636">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=2$\end{document}</tex-math></inline-formula>,&#x000a0; <inline-formula><tex-math id="d20e641">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R&#x0003e;16.7$\end{document}</tex-math></inline-formula>&#x000a0;for&#x000a0;<inline-formula><tex-math id="d20e646">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=1.3$\end{document}</tex-math></inline-formula>). </p><!--WRITE-PARA--><p id="p54">
        <fig id="fig-58"><!--WRITE-PARA--><p id="p55">
              <italic>FIGURE 1: Predispensing is beneficial (shaded area) when&#x000a0;<inline-formula><tex-math id="d20e659">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;&#x000a0;exceeds a certain threshold that depends on the
                projected demand.&#x000a0;&#x000a0;Here a supply adequate for&#x000a0;<inline-formula><tex-math id="d20e664">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T=20\%\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;&#x000a0;of the population is assumed, and predispensing
                  to&#x000a0;<inline-formula><tex-math id="d20e669">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q=3\%\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;&#x000a0;of the total population is under
                consideration.&#x000a0;&#x000a0;Also, we assume that treatment of a high-risk person
                with a predispensed course is twice as likely to be life-saving as if treatment is
                with a non-predispensed course, because predispensing allows earlier initiation of
                treatment (&#x000a0;<inline-formula><tex-math id="d20e674">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B=2\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;).&#x000a0;&#x000a0;For low projected demand
                  (below&#x000a0;<inline-formula><tex-math id="d20e679">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D&#x0003c;T-q=0.17\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;), there is no harm to predispensing, and predispensing even to
                groups that will gain below-average benefit from antivirals is better than no
                predispensing.&#x000a0;&#x000a0;For very high projected demand, (&#x000a0;<inline-formula><tex-math id="d20e685">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;&#x000a0;near 1), predispensing is beneficial even for very
                modest values of&#x000a0;<inline-formula><tex-math id="d20e690">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R$\end{document}</tex-math></inline-formula>, because competition for antivirals is strong, and predispensing has a
                relative benefit compared to acquisition by ill persons.&#x000a0;&#x000a0;For
                projected demand comparable to the supply (&#x000a0;<inline-formula><tex-math id="d20e695">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\approx T=0.2\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0;), predispensing is valuable only for groups for whom antivirals
                are considerably more valuable than the general population, because each course
                predispensed comes at the expense of someone else who could use it, yet it does not
                strongly increase the chance that a high-risk individual gets treated (since that
                individual would likely receive a course anyway without predispensing).&#x000a0;
              </italic>
            </p><graphic xlink:href="predispfig1"/></fig>
      </p><fig id="fig-61"><!--WRITE-PARA--><p id="p57">
            <italic>FIGURE 2: If predispensed courses are 1.3 more likely to be lifesaving than
              non-predispensed courses taken by the same person, the conditions for benefits of
              predispensing are more restrictive.&#x000a0;&#x000a0;Parameters are as in figure 1,
              except that <inline-formula><tex-math id="d20e713">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=1.3$\end{document}</tex-math></inline-formula>&#x000a0;&#x000a0;&#x000a0;In particular, in this situation if
              demand=supply, it is only beneficial to predispense a course if&#x000a0;<inline-formula><tex-math id="d20e718">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R&#x0003e;16.7$\end{document}</tex-math></inline-formula>
            </italic>
          </p><graphic xlink:href="fig-2-predispensing1"/></fig><!--WRITE-PARA--><p id="p59">Finally, we note that while it is beneficial to predispense antivirals if either of the
        conditions in the Main Result are met, it is not true in general that the benefit increases
        with the quantity of antivirals predispensed. Under certain conditions it would be better to
        predispense to a subset of the high-risk population.&#x000a0; This is discussed further in
        Appendix C, where a simple criterion is given ensuring that each successive predispensed
        dose increases the net benefit, provided that the quantity of antivirals predispensed is not
        too large.</p></sec><sec id="sec3"><title><bold>Interpretation of these Conditions</bold></title><!--WRITE-PARA--><p id="p61">Predispensing is most advantageous for groups that have the highest mortality rate
          (high&#x000a0;<inline-formula><tex-math id="d20e740">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula> ) and that benefit most from predispensed antivirals compared to non-predispensed
        ones (high&#x000a0;<inline-formula><tex-math id="d20e745">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula> ).&#x000a0; These factors capture the demand-independent aspect that it is useful
        to position antivirals with individuals who can be most helped by having them close at hand,
        rather than getting them after they become ill.&#x000a0; A second benefit of predispensing
        is to ensure access of antivirals to those who will benefit the most from them.&#x000a0;
        This benefit is greatest when demand is very high, because in such circumstances the
        high-risk individuals are very likely to need antivirals, but not to get them.&#x000a0; Thus
        the benefits of predispensing are greatest for larger values of <inline-formula><tex-math id="d20e750">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula> , <inline-formula><tex-math id="d20e755">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula> , and&#x000a0;<inline-formula><tex-math id="d20e760">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D/T\end{equation*}\end{document}</tex-math></inline-formula> .&#x000a0; The costs of predispensing &#x02013; lost opportunities for
        individuals who do not receive predispensed courses &#x02013; are zero when demand is low
        enough (as all who need the antivirals can receive them) then increase, but not as fast as
        the benefits.&#x000a0; Qualitatively, then, predispensing is most advantageous when demand
        is very high or very low, and least likely to be advantageous when demand just exceeds
        supply.&#x000a0; Even there, however, if the benefit of a predispensed course is
        significantly larger than that of a non-predispensed course, predispensing is valuable for
        individuals who can benefit more from treatment than the general population. </p></sec><sec id="sec4"><title><bold>Risks of Predispensing</bold></title><!--WRITE-PARA--><p id="p62">The major risk of predispensing is that courses that would otherwise be life-saving (when
        used from the stockpile) will be predispensed, then not used by someone for whom they would
        be more likely to be life-saving.&#x000a0; We can consider what has been written so far from
        another perspective: this risk is most acute when demand is near supply ( <inline-formula><tex-math id="d20e771">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T\approx D\end{equation*}\end{document}</tex-math></inline-formula> ) , when individuals not in the group to be predispensed would benefit from
        treatment by predispensed antivirals which won&#x02019;t be used, and when predispensing and
        consequent early use are not very beneficial (reducing&#x000a0;<inline-formula><tex-math id="d20e776">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula> ). </p><!--WRITE-PARA--><p id="p63">The idea of predispensing was previously considered in the context of pre-pandemic sale of
        antiviral &#x0201c;Medkits,&#x0201d; special packaging of oseltamivir or zanamivir for home
        storage to be saved until a pandemic occurred.&#x000a0; A number of concerns were raised
        regarding such Medkits, resulting eventually in a lack of approval by the Food and Drug
        Administration (<ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4385m1-final.pdf">www.fda.gov/ohrms/dockets/ac/08/minutes/2008-4385m1-final.pdf</ext-link>). One of these concerns
        was the issue of equity - if Medkits were to be purchased by individuals, individual
        decision making and ability to pay&#x000a0;would influence access. Another concern was the
        risk of inappropriate use or wastage.&#x000a0; A key difference between pre-pandemic
        distribution of antivirals and predispensing just prior to or in the middle of a wave of
        pandemic influenza is that the time frame for wastage is much shorter in the present case.
        Thus, we expect that <inline-formula><tex-math id="d20e786">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;will primarily reflect the advantage of early vs. delayed treatment, for
        which there is evidence <xref ref-type="bibr" rid="ref-3070768605">[1]</xref>
        <xref ref-type="bibr" rid="ref-2509778060">[2]</xref>
        <xref ref-type="bibr" rid="ref-2593680428">[3]</xref>
        <xref ref-type="bibr" rid="ref-2321005289">[4]</xref>
        <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>. </p><!--WRITE-PARA--><p id="p64">It is also worth mentioning that unlike the situation with antibacterial medications
        &#x02013; which can promote drug resistance even when used to treat non-bacterial
        infections, because of their effect on bystander flora <xref ref-type="bibr" rid="ref-2583398228">[23]</xref>, anti-influenza drugs do not promote resistance when used to treat non-influenza
        infections.&#x000a0; In the current H1N1 pandemic, resistance levels appear to be very low
        &#x02013; for instance in the UK, where extensive antiviral usage takes place, resistance
        levels were estimated to be 0.17% <xref ref-type="bibr" rid="ref-779459754">[24]</xref>. Moreover, prior mathematical modeling studies <xref ref-type="bibr" rid="ref-3773165249">[25]</xref>
        <xref ref-type="bibr" rid="ref-1040828799">[26]</xref>&#x000a0;have shown that if the epidemic is already large (as it is now) at the
        time that large-scale antiviral treatment begins, then resistant strains will be unlikely to
        ascend to high frequency in the population before the epidemic is over, even in the absence
        of vaccination. Thus we think that additional antiviral usage which may result from
        predispensing will have a very minor impact on antiviral resistance levels in the current
        H1N1 pandemic.<bold>&#x000a0;</bold>
      </p></sec><sec id="sec5"><title>
        <bold>Benefits of early antiviral treatment for preventing severe outcomes.</bold>
    </title><!--WRITE-PARA--><p id="p65">A key source of uncertainty in our estimates is the relative benefit <inline-formula><tex-math id="d20e832">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;for preventing a severe outcome by a predispensed course of antivirals
        vs. one obtained by prescription by an individual who would die otherwise. In this section
        we describe data from <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;showing a reduction in probability of a severe outcome resulting from
        early antiviral treatment. We also explain why it is difficult to estimate <inline-formula><tex-math id="d20e843">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula> from data. </p><!--WRITE-PARA--><p id="p66">Data in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;show that among hospitalized H1N1pdm patients, 18/357 (5%) of those who
        received antiviral treatment within 48 hours died; the same numbers for all patients who
        received any antiviral treatment are 70/701 (10%).&#x000a0; If we think of those
        hospitalized patients who received antivirals within 48 hours as a proxy for the
        predispensed individuals who would progress into a severe condition, and all individuals in
        the study who received antivirals as a proxy for individuals who would progress into a
        severe condition and receive antivirals during the epidemic, then ratio of probabilities
        1.98=(70/701)/(18/357) can be though of as a ratio of probabilities of dying given that you
        receive antivirals upon infection during the course of the epidemic vs. having a
        predispensed course.&#x000a0;&#x000a0;&#x000a0;</p><!--WRITE-PARA--><p id="p67">Data in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;show that among hospitalized H1N1pdm patients, 13/75 (17.3%) of those who
        received antiviral treatment within 48 hours were either transferred to ICU or died; the
        same numbers for all patients who received any antiviral treatment are 56/200
        (28%).&#x000a0; Using the same proxies as above, the ratio of probabilities
        1.62=(56/200)/(13/75) can be though of as a ratio of probabilities of being transferred to
        ICU or dying given that you receive antivirals upon infection during the course of the
        epidemic vs. having a predispensed course.</p><!--WRITE-PARA--><p id="p68">Those proxies may be inaccurate. Having antivirals predispensed may work better than merely
        receiving them within 48 hours after symptom onset. Additionally, both datasets are based on
        a time period before the CDC guidelines on Sep. 8, 2009 <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>&#x000a0;recommending prompt treatment of symptomatic high-risk individuals
        without a lab test confirmation; at the same time, those datasets address hospital patients,
        many of whom received antivirals promptly, presumably upon a first doctor visit.</p><!--WRITE-PARA--><p id="p69">Regardless of whether the proxies are accurate, they do not yield enough information to get
        an estimate of <inline-formula><tex-math id="d20e865">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>, the relative benefit of preventing a severe outcome (death or ICU admission) by
        a predispensed course vs. a course obtained upon infection by a person who would progress
        into this outcome otherwise. To see that, coming back to the study in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>, let <inline-formula><tex-math id="d20e873">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$p$\end{document}</tex-math></inline-formula>&#x000a0;be the proportion of hospitalized patients who would die or need to be
        transferred to ICU unless they receive antivirals. The relative benefit of preventing a
        severe outcome is then </p><p>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
          &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;<disp-formula><tex-math id="d20e880">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$\frac{p-0.173}{p-0.28}$\end{document}</tex-math></disp-formula>
      </p><!--WRITE-PARA--><p id="p71">Here the numerator represents individuals who were spared a bad outcome because of early
        antiviral treatment, and the denominator represents individuals who were spared a bad
        outcome because of any antiviral treatment. Thus if <inline-formula><tex-math id="d20e887">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$p=0.35$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="d20e892">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=2.52$\end{document}</tex-math></inline-formula>; if <inline-formula><tex-math id="d20e897">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$p=0.5$\end{document}</tex-math></inline-formula>, <inline-formula><tex-math id="d20e902">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B=1.48$\end{document}</tex-math></inline-formula>&#x000a0;etc. Data in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;show that among hospital admissions who never took antivirals, 9/68
        (13.25%) either died or were transferred to ICU. It appears that people who did not take
        antivirals fared best; for the data in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>, they fared slightly worse than people who took antivirals after 48 hours since
        symptom onset. This is due to a bias that we already encountered in <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>&#x000a0;&#x02013; bad, deteriorating cases were given late antivirals; as a
        consequence, the group without antivirals has a disproportionate share of good cases. In
        other words, given high levels of treatment, the reverse causal relation between treatment
        and outcome makes an estimate of the treatment effect difficult. </p><!--WRITE-PARA--><p id="p72">While we cannot render an estimate of <inline-formula><tex-math id="d20e919">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;from data, we note that 59/268&#x000a0;(22%) of patients in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>&#x000a0;neither received antivirals nor died or were admitted to ICU. Thus we
        estimate that <inline-formula><tex-math id="d20e927">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$p\leq 1-0.22=0.78$\end{document}</tex-math></inline-formula>&#x000a0;and hence <inline-formula><tex-math id="d20e932">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B\geq 1.21$\end{document}</tex-math></inline-formula>. An equality would be a very conservative estimate, which assumes that all the
        144 individuals who were treated with antivirals and did not die and were not transferred to
        ICU had a good outcome because of antiviral treatment. There are additional reasons why this
        is an underestimate of <inline-formula><tex-math id="d20e937">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>. Data from <xref ref-type="bibr" rid="ref-3446914576">[27]</xref>&#x000a0;suggests that 17% of H1N1 deaths were never hospitalized, and some of
        them could have benefited from predispensing. Additionally our estimates on the chances of
        avoiding ICU admission or death are based on hospitalized patients, while some people could
        avoid hospitalization by using a predispensed course of antivirals.&#x000a0; We believe that
        in reality <inline-formula><tex-math id="d20e946">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;should be bigger than 1.21. </p></sec><sec id="sec6"><title>
      <bold>Implications for Decision Making</bold>
      </title><!--WRITE-PARA--><p id="p73">On current evidence, we believe that there are groups in the population for whom the
        relative risk <inline-formula><tex-math id="d20e960">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R$\end{document}</tex-math></inline-formula>&#x000a0;of death or of other severe outcomes, such as hospitalization,
        substantially exceeds 1.&#x000a0; These groups include pregnant women <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-2436736239">[8]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
        <xref ref-type="bibr" rid="ref-3342172176">[28]</xref>, children and adults with neurological conditions <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
        <xref ref-type="bibr" rid="ref-3911190679">[29]</xref>, persons with immunosuppression and certain chronic diseases <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>
        <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>,&#x000a0; morbidly obese individuals (BMI <inline-formula><tex-math id="d20e997">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$\geq 40$\end{document}</tex-math></inline-formula>) <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>, and some of the other high-risk groups&#x000a0; <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-374826205">[22]</xref>
        <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>.&#x000a0; We believe it is also plausible to expect that predispensed antivirals
        are more likely to be life-saving (or to prevent hospitalizations or other severe outcomes)
        than those that are not predispensed (<inline-formula><tex-math id="d20e1018">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B&#x0003e;1$\end{document}</tex-math></inline-formula>), because wastage is relatively unlikely given the short time frame between when
        predispensing and usage could occur, and because early treatment is likely to have benefits
        in preventing progression to more severe condition <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>
        <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>.&#x000a0; </p><!--WRITE-PARA--><p id="p74">At the same time, given the generally mild nature of H1N1 infections, a number of developed
        countries with large antiviral stockpiles will likely have antiviral supply greatly
        exceeding population demand. The same conclusions appear to be valid for the US, which has a
        relatively small stockpile compared to some countries, but also a restrictive antiviral
        usage policy for low-risk individuals <xref ref-type="bibr" rid="ref-3139123044">[13]</xref>.&#x000a0; Under these conditions<bold>, </bold>predispensing a quantity of antivirals
        not exceeding the difference between supply and demand is always beneficial.</p><!--WRITE-PARA--><p id="p75">Even if one is uncertain about the population demand for antivirals during the course of
        the epidemic, one can include certain categories of individuals for predispensing given a
        measure of belief about the relative benefit <inline-formula><tex-math id="d20e1042">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>.&#x000a0;&#x000a0;We concentrate on the situation in the US; in particular, we
        assume that the available antiviral stockpile can cover 20%&#x000a0;of the population. </p><!--WRITE-PARA--><p id="p76">If one thinks that <inline-formula><tex-math id="d20e1049">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;is as low as 1.3 (Figure 2), one can still, regardless of the demand
        levels, include certain groups like immunocompromised children. One should probably also
        include immunocompromised adults due to a high relative risk for fatality (16.1) resulting
        from a large study <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. People with neurological disorders should probably also be included due to high
        rates of hospitalizations, fatalities and ICU admissions in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. If one thinks that <inline-formula><tex-math id="d20e1063">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;is at least 2 (Figure 1), one should include additional groups in the
        predispensing category, such as pregnant women, morbidly obese adults, and possibly some
        additional groups for which we have no prevalence data. </p><!--WRITE-PARA--><p id="p77">We again want to emphasize that the above considerations apply given uncertainty whether
        supply surpasses demand. If one believes that supply does exceed demand (which appears to be
        relevant for several countries, including US), predispensing a quantity of antivirals not
        exceeding the difference between supply and demand is beneficial.</p></sec><sec id="sec7"><title><bold>Discussion</bold>
      </title><!--WRITE-PARA--><p id="p78">In the setting of an autumn wave of pandemic influenza in developed countries of the
        Northern Hemisphere that already possess significant antiviral stockpiles, predispensing of
        a portion of these stockpiles to individuals at high risk of severe outcome of infection may
        be a means to prevent death and other severe outcomes by improving the efficiency of use of
        a limited stockpile.&#x000a0; In this paper we consider the net benefits of a predispensing
        policy, where the measure of the benefit is the number of severe outcomes (such as deaths or
        hospitalizations) prevented by antivirals in the whole population.&#x000a0;</p><!--WRITE-PARA--><p id="p79">Determination whether such a policy is beneficial depends on the assumptions one makes. One
        general set of assumptions which appears relevant to a number of developed countries is as
        follows: antiviral supply exceeds demand, and predispensing antivirals is beneficial to the
        category of individuals to whom antivirals were predispensed. Under those assumptions,
        predispensing a quantity of antivirals not exceeding the difference between supply and
        demand is always beneficial.&#x000a0;</p><!--WRITE-PARA--><p id="p80">If one is uncertain about the overall population demand for antivirals, predispensing to
        certain high-risk groups may still be justified under the assumptions of our Main Result and
        Appendix A; our conclusions based on available H1N1pdm data are summarized in Implications
        for Decision Making section. One additional assumption that should be highlighted in this
        context is that, as used in the absence of predispensing, antivirals are equally likely to
        save the life of a treated member of the high-risk group as a treated member of the general
        population given that both of them would die without treatment.&#x000a0; If treatment is
        less effective among members of high-risk groups who would die without treatment, then the
        benefits of predispensing are reduced; if it is more effective, they may be increased.</p><!--WRITE-PARA--><p id="p81">A key source of uncertainty in our estimates is the relative benefit <inline-formula><tex-math id="d20e1083">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;for preventing a severe outcome by a predispensed course of antivirals
        vs. one obtained by prescription by an individual who would otherwise have a severe outcome.
        &#x000a0;This benefit should be assessed against a strategy of identifying high risk
        persons, educating them to contact their provider for symptoms, and encouraging providers to
        provide rapid empiric therapy including via telephone. While there is no data to assess
          <inline-formula><tex-math id="d20e1088">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$B$\end{document}</tex-math></inline-formula>&#x000a0;directly, we have estimated the reduction in probability of a severe
        outcome by early antiviral treatment based on data in <xref ref-type="bibr" rid="ref-1556464731">[5]</xref>
        <xref ref-type="bibr" rid="ref-3562892496">[6]</xref>. <xref ref-type="bibr" rid="ref-2321005289">[4]</xref>&#x000a0;gives additional evidence that early antiviral administration is
        beneficial in preventing severe outcomes. Similarly, there is evidence that a policy
        allowing for broader vs. more limited use of antivirals in symptomatic individuals is
        beneficial for reducing mortality <xref ref-type="bibr" rid="ref-1200866011">[30]</xref>; this benefit was observed both on a population level (Chile vs. Argentina), and
        in a category of pregnant women. </p><!--WRITE-PARA--><p id="p82">We have avoided cost-effectiveness considerations in our analysis as there are several
        unknowns involved, including the cost of predispensed antivirals (government vs. private
        rates). We note however that for some groups with the highest risk for severe outcomes, such
        as immunocompromised children, predispensing may be, among other things, cost effective.</p><!--WRITE-PARA--><p id="p83">Yet another potential issue related to predispensing is complacency, namely individuals
        with predispensed antivirals might get a sense of false security &#x000a0;and not exercise
        enough care in terms of avoiding getting infected. On the other hand, people with high risk
        conditions to whom drugs were predispensed when they are not sick may be more alert about
        the risks that influenza poses to them; predispensing may also heighten awareness about high
        risk groups in the medical community.</p><!--WRITE-PARA--><p id="p84">Finally, we would recommend that the total proportion of the stockpile predispensed be
        limited (perhaps to 20% of the stockpile or less). There are several reasons for that. One
        of them is that the conditions defined in this paper guarantee that predispensing is
        beneficial in terms of decreasing the mortality provided certain assumptions about temporal
        patterns of antiviral distribution hold. The most flexible assumption we require is
        assumption b) in Appendix A. This assumption may be violated under the following scenario:
        antiviral supply nears depletion and only the most severe cases get antivirals. To deal with
        such a scenario, we recommend to set aside a certain quantity of antivirals for
        safekeeping.</p></sec><sec id="sec8"><title>
        <bold>Acknowledgments</bold>
      </title><!--WRITE-PARA--><p id="p85">We thank Richard Hatchett for helpful discussions.&#x000a0;&#x000a0;</p><!--WRITE-PARA--><p id="p86">The MIDAS High Risk Segmentation Group (D. Wagener, R. Zimmerman, D. Lauderdale) kindly
        shared the data from <xref ref-type="bibr" rid="ref-1110531368">[18]</xref>.</p></sec><sec id="sec9"><title>
        <bold>Funding Information</bold>:</title><!--WRITE-PARA--><p id="p87">This work was funded by the US National Institutes of Health
        Models of Infectious Disease Agent Study Cooperative Agreements 5U01GM076497 and
        1U54GM088588 to ML for the Harvard Center for Communicable Disease Dynamics (ML,EG,JO), and
        by the RAPIDD program of the Science &#x00026; Technology Directorate, Department of Homeland
        Security, and the Fogarty International Center, National Institutes of Health (JCM). </p></sec><sec id="sec10"><title>
        <bold>Competing Interests</bold>
      </title><!--WRITE-PARA--><p id="p88">ML discloses consulting fees from the Avian/Pandemic Flu Registry (Outcome Sciences),
        funded in part by Roche.<bold>&#x000a0;</bold> All other authors declare no competing
        interests.</p><!--WRITE-PARA--><p id="p89">
        <bold>
          &#x02028;
        </bold>
      </p></sec><sec id="sec11"><title>
        <bold>APPENDIX: </bold>
      </title><!--WRITE-PARA--><p id="p90">
        <bold>&#x000a0;</bold>
      </p><sec id="sec12"><title>
        <bold>A.&#x000a0; Justification of the Main Result</bold>
      </title><!--WRITE-PARA--><p id="p91">In this Appendix we derive the main result by calculating or finding a bound on the number
        of lives saved by antiviral treatment in the high risk group (a proportion <inline-formula><tex-math id="d20e1170">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula> ) and in what we term the &#x0201c;general population,&#x0201d; which is the
        total population without the high risk individuals, a proportion&#x000a0; <inline-formula><tex-math id="d20e1175">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}1-q\end{equation*}\end{document}</tex-math></inline-formula> .&#x000a0; </p><!--WRITE-PARA--><p id="p92">Let us first list the assumptions we are making about the temporal patterns of antiviral
        demand used in out Main Result:</p><!--WRITE-PARA--><p id="p93"> a)&#x000a0;&#x000a0;&#x000a0; For condition (ii) to imply the benefit of predispensing, we
        need that among the people who receive antivirals, the proportion of them who would die
        otherwise doesn&#x02019;t change in time.</p><!--WRITE-PARA--><p id="p94"> b)&#x000a0;&#x000a0; &#x000a0;For conditions (iii) and (iv) to imply the benefit of
        predispensing, we need that among the people who receive antivirals, the proportion of them
        who would die otherwise doesn&#x02019;t increase in time. </p><!--WRITE-PARA--><p id="p95"> c)&#x000a0;&#x000a0;&#x000a0; For condition (i), no additional assumptions are needed.</p><!--WRITE-PARA--><p id="p96">Condition b) is more flexible than a) and can be interpreted as follows: consider persons
        infected during the epidemic. As time progresses, the proportion of them who will require
        antivirals may increase due to panic, etc. - suppose the increase is by a factor
          of&#x000a0;<inline-formula><tex-math id="d20e1190">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}X\end{equation*}\end{document}</tex-math></inline-formula> . The people who would die without antivirals are the severe cases and the
        proportion of them who receives antivirals (given availability) is probably large - thus
        even if it increases it time, we assume that the increase is by a factor of at most <inline-formula><tex-math id="d20e1195">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}X\end{equation*}\end{document}</tex-math></inline-formula> . </p><!--WRITE-PARA--><p id="p97">There are four conditions to consider: </p><sec id="sec13"><title>
        <bold>Condition (i): Supply exceeds demand even after predispensing&#x000a0;<inline-formula><tex-math id="d20e1209">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T-q&#x0003e;D\end{equation*}\end{document}</tex-math></inline-formula> and&#x000a0;<inline-formula><tex-math id="d20e1214">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e;1\end{equation*}\end{document}</tex-math></inline-formula>
        </bold>&#x000a0; </title><!--WRITE-PARA--><p id="p99">In this case all persons in the general population who demand antivirals would get them
        under the no predispensing scenario &#x02013; thus predispensing would result in no loss of
        lives in that category compared to no predispensing. Since&#x000a0; <bold>
          <inline-formula><tex-math id="d20e1224">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e;1\end{equation*}\end{document}</tex-math></inline-formula>
        </bold> , persons to whom antivirals were predispensed are more likely to survive under
        predispensing than through acquiring antivirals during the epidemic. Moreover no all among
        them who need antivirals would necessarily acquire them during the epidemic &#x02013; thus
        predispensing is clearly beneficial. </p></sec><sec id="sec14"><title>
        <bold>Condition (ii): In the absence of predispensing, demand exceeds supply, <inline-formula><tex-math id="d20e1237">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D&#x0003e;T\end{equation*}\end{document}</tex-math></inline-formula>
        </bold>
      </title><!--WRITE-PARA--><p id="p101">To fix notation, let&#x000a0;<inline-formula><tex-math id="d20e1245">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D'\geq D\end{equation*}\end{document}</tex-math></inline-formula> be the demand for antivirals in the total population in the absence of
        predispensing. </p><!--WRITE-PARA--><p id="p102">Among the <inline-formula><tex-math id="d20e1252">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;individuals in the high risk group,&#x000a0;<inline-formula><tex-math id="d20e1257">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRp_d\end{equation*}\end{document}</tex-math></inline-formula> of them would die without antivirals. Out of those,&#x000a0;<inline-formula><tex-math id="d20e1262">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRBp_dp_s\end{equation*}\end{document}</tex-math></inline-formula> will be saved by predispensed antivirals. Under no predispensing, not all of
        those <inline-formula><tex-math id="d20e1267">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRp_d\end{equation*}\end{document}</tex-math></inline-formula> people may demand antivirals, and among those who do, a fraction <inline-formula><tex-math id="d20e1272">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T}{D'}\leq \frac{T}{D}\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;of them would get antivirals, so&#x000a0;<inline-formula><tex-math id="d20e1278">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRp_dp_s\frac{T}{D'}\end{equation*}\end{document}</tex-math></inline-formula> lives would be saved (Table 2). </p><!--WRITE-PARA--><p id="p104">TABLE 2: Numbers of lives saved in the general population and high risk group under no
        predispensing vs. predispensing, condition (ii) (demand exceeds supply)</p><!--WRITE-PARA--><p id="p105">
        <table-wrap id="d20e1291"><table width="592" border="1" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                  <bold>&#x000a0;</bold>
                </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                  <bold>No predispensing</bold>
                </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                  <bold>Predispensing</bold>
                </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">General population</td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">&#x000a0;&#x000a0; &#x000a0; &#x000a0;&#x000a0;<inline-formula><tex-math id="d20e1319">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T}{D'}L\end{equation*}\end{document}</tex-math></inline-formula>
                </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">&#x000a0;&#x000a0; &#x000a0;<inline-formula><tex-math id="d20e1327">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T-q}{D}L\end{equation*}\end{document}</tex-math></inline-formula>
                </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">High-risk group</td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">at most <inline-formula><tex-math id="d20e1339">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T}{D'}qRp_dp_s\end{equation*}\end{document}</tex-math></inline-formula>
                </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">&#x000a0;<inline-formula><tex-math id="d20e1347">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRBp_dp_s\end{equation*}\end{document}</tex-math></inline-formula>
                </td></tr></tbody></table></table-wrap>
      </p><!--WRITE-PARA--><p id="p116">Turning now to the general population, if all the demand was met, the total number of lives
        saved without predispensing would be <inline-formula><tex-math id="d20e1359">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\end{equation*}\end{document}</tex-math></inline-formula>.&#x000a0; However, given scarcity, only&#x000a0;&#x000a0;&#x000a0;<inline-formula><tex-math id="d20e1364">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T}{D'}L\end{equation*}\end{document}</tex-math></inline-formula> lives are saved (Table 2), because the remaining individuals do not receive
        antivirals.&#x000a0; If antivirals are predispensed, the remaining demand is <inline-formula><tex-math id="d20e1369">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;and the supply is <inline-formula><tex-math id="d20e1374">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T-q\end{equation*}\end{document}</tex-math></inline-formula> . Thus a fraction <inline-formula><tex-math id="d20e1379">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T-q}{D}\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;of&#x000a0; the demand in the general population is met, and the number
        of lives saved is thus <inline-formula><tex-math id="d20e1385">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T-q}{D}L\end{equation*}\end{document}</tex-math></inline-formula> (Table 2).&#x000a0;&#x000a0; </p><!--WRITE-PARA--><p id="p118">Using these figures (summarized in Table 2), there is a net gain in lives saved if the
        total number saved under predispensing exceeds that saved without predispensing, that is, if </p><!--WRITE-PARA--><p id="p119">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        (A1)&#x000a0;&#x000a0; <inline-formula><tex-math id="d20e1396">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$L\frac{T - q}{D} + qRBp_d p_s \geq L\frac{T}{D'} + qRp_d p_s \frac{T}{D'}$\end{document}</tex-math></inline-formula> . </p><!--WRITE-PARA--><p id="p120">Rearranging and dividing by&#x000a0;<inline-formula><tex-math id="d20e1404">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q&#x0003e;0\end{equation*}\end{document}</tex-math></inline-formula> , we obtain the condition <inline-formula><tex-math id="d20e1409">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$L\left(\frac{1}{D} + \frac{T}{q}\left[ \frac{1}{D'} - \frac{1}{D}\right]\right)
            \leq Rp_d p_s B - Rp_d p_s \frac{T}{{D'}}$\end{document}</tex-math></inline-formula> .&#x000a0; Using the facts that&#x000a0;<inline-formula><tex-math id="d20e1414">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D'\geq D\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; and <inline-formula><tex-math id="d20e1419">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L \le p_s p_d \end{equation*}\end{document}</tex-math></inline-formula> , a sufficient condition is then </p><!--WRITE-PARA--><p id="p121">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        &#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        (A2) <inline-formula><tex-math id="d20e1426">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{1}{D} \le R(B - T/D)\end{equation*}\end{document}</tex-math></inline-formula>
      </p><!--WRITE-PARA--><p id="p122">which is condition (ii) so long as <inline-formula><tex-math id="d20e1433">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B&#x0003e;T/D\end{equation*}\end{document}</tex-math></inline-formula>. </p></sec><sec id="sec15"><title>
        <bold>Condition (iii)&#x000a0;<inline-formula><tex-math id="d20e1446">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$T - q \le D \le T$\end{document}</tex-math></inline-formula>
        </bold>
      </title><!--WRITE-PARA--><p id="p124">The argument is similar to the previous case. </p><!--WRITE-PARA--><p id="p125">Among the high-risk group, without predispensing nearly all or all demand will be satisfied
        (there may be some competition if <inline-formula><tex-math id="d20e1456">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$D \le T \le D'$\end{document}</tex-math></inline-formula> ), so at most&#x000a0;<inline-formula><tex-math id="d20e1461">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRp_dp_s\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; lives will be saved.&#x000a0; With predispensing, the situation will be
        as above. </p><!--WRITE-PARA--><p id="p126">Among the general population, without predispensing, at most&#x000a0; <inline-formula><tex-math id="d20e1468">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; lives will be saved.&#x000a0;&#x000a0; With predispensing, however, the
        situation will be as similar to Condition (ii), with equality replaced by inequality due to
        condition (b).&#x000a0; This is summarized in Table 3.&#x000a0; Repeating the comparison of
        equation (A1) for the entries in Table 3, we obtain Condition (iii). </p><!--WRITE-PARA--><p id="p128">TABLE 3: Numbers of lives saved in the general population and high risk group under no
        predispensing vs. predispensing, Case 3 (supply exceeds demand before predispensing, but not
        after)</p><table-wrap id="d20e1479"><table border="1" cellpadding="0" cellspacing="0"><tbody><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                <bold>&#x000a0;</bold>
              </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                <bold>No predispensing</bold>
              </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                <bold>Predispensing</bold>
              </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">General population<break/>&#x000a0;</td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">at most <inline-formula><tex-math id="d20e1509">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}L\end{equation*}\end{document}</tex-math></inline-formula>
              </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">at least <inline-formula><tex-math id="d20e1517">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\frac{T-q}{D}L\end{equation*}\end{document}</tex-math></inline-formula>
              </td></tr><tr><td valign="top" rowspan="1" colspan="1" style="width:2.05in">High-risk group</td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">at most <inline-formula><tex-math id="d20e1529">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRp_dp_s\end{equation*}\end{document}</tex-math></inline-formula>
                &#x02028;
              </td><td valign="top" rowspan="1" colspan="1" style="width:2.05in">
                <inline-formula><tex-math id="d20e1539">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}qRBp_dp_s\end{equation*}\end{document}</tex-math></inline-formula>
                &#x02028;
              <break/>&#x000a0;&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec id="sec16"><title>
        <bold>Condition (iv) no assumptions on demand.</bold>
      </title><!--WRITE-PARA--><p id="p141">If <inline-formula><tex-math id="d20e1558">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$D \leq T$\end{document}</tex-math></inline-formula>&#x000a0;, the result follows from Conditions (i) and (iii), since they use the
        same assumption b) as condition (iv). If&#x000a0;<inline-formula><tex-math id="d20e1563">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$D&#x0003e;T$\end{document}</tex-math></inline-formula>, the argument is similar to condition (iii), replacing&#x000a0;<inline-formula><tex-math id="d20e1568">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$L$\end{document}</tex-math></inline-formula>&#x000a0;by the number of individuals saved by the first <inline-formula><tex-math id="d20e1573">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$T$\end{document}</tex-math></inline-formula>&#x000a0;courses of antivirals in the general population. </p></sec></sec><sec id="sec17"><title>
        <bold>B.&#x000a0; Formal description of the parameters <inline-formula><tex-math id="d20e1587">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}p_s\end{equation*}\end{document}</tex-math></inline-formula> ,&#x000a0;<inline-formula><tex-math id="d20e1592">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}R\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; and&#x000a0;<inline-formula><tex-math id="d20e1597">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}B\end{equation*}\end{document}</tex-math></inline-formula> . </bold>&#x000a0; </title><!--WRITE-PARA--><p id="p143">Suppose that for every individual who is either a member of the high risk group <inline-formula><tex-math id="d20e1605">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}G=h\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;or the total population <inline-formula><tex-math id="d20e1610">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}G=w\end{equation*}\end{document}</tex-math></inline-formula> , we can define an outcome <inline-formula><tex-math id="d20e1615">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}O(T)\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;that depends on the (possibly counterfactual) treatment&#x000a0;<inline-formula><tex-math id="d20e1620">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T\end{equation*}\end{document}</tex-math></inline-formula> received, where either&#x000a0;<inline-formula><tex-math id="d20e1625">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}O=d\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; (died) or <inline-formula><tex-math id="d20e1631">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}O=s\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; (survived) and either&#x000a0; <inline-formula><tex-math id="d20e1636">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T=U\end{equation*}\end{document}</tex-math></inline-formula> (untreated), or <inline-formula><tex-math id="d20e1641">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T=S\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;(treated from the stockpile), or <inline-formula><tex-math id="d20e1646">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}T=P\end{equation*}\end{document}</tex-math></inline-formula> (treated from a predispensed course, and that course has not been previously
        wasted).&#x000a0; Then </p><p>
        <disp-formula><tex-math id="d20e1655">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ \begin{array}{l} p_D = \Pr [O(U) = d|G = w] \\ p_S = \Pr [O(S) = s|O(U) = d] =
            \Pr [O(S) = s|O(U) = d,G = w] = \Pr [O(S) = s|O(U) = d,G = h] \end{array} \]\end{equation*}\end{document}</tex-math></disp-formula>
        
      </p><p>
        <disp-formula><tex-math id="d20e1664">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ \begin{array}{l} R = \frac{{\Pr [O(U) = d|G = h]}}{{\Pr [O(U) = d|G = w]}} \\ B
            = \frac{{\Pr [O(P) = s|O(U) = d,G = h]}}{{\Pr [O(S) = s|O(U) = d,G = h]}} \\ \end{array}
            \]\end{equation*}\end{document}</tex-math></disp-formula>
      </p><!--WRITE-PARA--><p id="p147">We are interested in the probability that treatment (nonpredispensed) will save a life in
        the total population, which is </p><p>
        <disp-formula><tex-math id="d20e1675">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ p_d p_s = \Pr [O(U) = d,O(S) = s|G = w] \]\end{equation*}\end{document}</tex-math></disp-formula> , </p><!--WRITE-PARA--><p id="p151">in the probability that treatment without predispensing will save a life in the high-risk
        group, which is </p><p>
        <disp-formula><tex-math id="d20e1686">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ \begin{array}{l} p_D p_S R = \Pr [O(U) = d|G = h]\frac{{\Pr [O(U) = d|G =
            h]}}{{\Pr [O(U) = d|G = w]}}\Pr [O(S) = s|O(U) = d,G = h] \\ = \Pr [O(S) = s,O(U) = d|G
            = h] \\ \end{array} \]\end{equation*}\end{document}</tex-math></disp-formula> &#x000a0; </p><!--WRITE-PARA--><p id="p153">and in the probability that a high risk person who received a predispensed course would
        thereby have his life saved, which is </p><p>
        <disp-formula><tex-math id="d20e1696">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ p_D p_S RB = \Pr [O(T) = s,O(U) = d|G = h] \]\end{equation*}\end{document}</tex-math></disp-formula>
      </p></sec><sec id="sec18"><title>
        <bold>C. When does the benefit increase with the number of courses predispensed?</bold>
        
      </title><!--WRITE-PARA--><p id="p156">While predispensing to high risk groups is beneficial compared to no predispensing, if
        condition (iv) holds, it is not true in general that the benefit of predispensing increases
        with the quantity of antivirals predispensed. Consider for example one high risk group whose
        size equals (or surpasses) the antiviral supply.&#x000a0; As we keep on predispensing,
        coverage level for the rest of the population goes to&#x000a0;0&#x000a0; while the relative
        risk of dying in the high risk group stays uniformly bounded. Thus at some point equation
        (iv) will be violated (with the new coverage level and the relative risk), and in fact it is
        not advisable to predispense the whole supply to the group under no a-priori assumptions on
        the demand&#x000a0; <inline-formula><tex-math id="d20e1715">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}D\end{equation*}\end{document}</tex-math></inline-formula> . However the have the following simple criterion: &#x000a0; &#x02028;
      </p><!--WRITE-PARA--><p id="p157">BENEFIT INCREASES WITH THE AMOUNT PREDISPENSED: </p><!--WRITE-PARA--><p id="p158">Suppose the relative risk of dying&#x000a0; <inline-formula><tex-math id="d20e1726">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$R \ge 1$\end{document}</tex-math></inline-formula> , and assumption b) in Appendix A holds. The benefit of predispensing is
        guaranteed to increase with quantity of antivirals predispensed as long as the total
        quantity <inline-formula><tex-math id="d20e1731">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula>of antivirals predispensed obeys </p><!--WRITE-PARA--><p id="p159">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
          (C1)<inline-formula><tex-math id="d20e1738">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
$\frac{{T - q}}{{1 - q}} \ge \frac{1}{{R(B - 1)}}$\end{document}</tex-math></inline-formula>&#x000a0; </p><!--WRITE-PARA--><p id="p160">To show this, let the quantity <inline-formula><tex-math id="d20e1745">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0;of antivirals predispensed obey the inequality (C1). To show that the
        benefit of predispensing was increasing, take any intermediate quantity <inline-formula><tex-math id="d20e1750">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q_I\leq q\end{equation*}\end{document}</tex-math></inline-formula> . We need the show that equation (C1) was still true after predispensing&#x000a0;
          <inline-formula><tex-math id="d20e1755">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q_I\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; courses of antivirals. Note that after this predispensing, the coverage
        level and the relative risks have changed. The coverage level became </p><!--WRITE-PARA--><p id="p161">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
        (C2) <inline-formula><tex-math id="d20e1762">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}\[ T_I = \frac{{T - q_I }}{{1 - q_I }} \ge \frac{{T - q}}{{1 - q}} \ge
            \frac{1}{{R(B - 1)}} \]\end{equation*}\end{document}</tex-math></inline-formula> &#x000a0; </p><!--WRITE-PARA--><p id="p162">Also, as a result of predispensing, we've removed some individuals with the risk of dying
        higher than the one for the general population. Thus the probability of dying for an average
        individual left after predispensing is lower than the one before predispensing; hence the
        relative risks of the high risk groups have only increased. Since equation (C2) for the new
        coverage level holds with original relative risks, condition (iv) in our Main Result holds
        with the new coverage levels and relative risks (after predispensing&#x000a0;<inline-formula><tex-math id="d20e1769">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q_I\end{equation*}\end{document}</tex-math></inline-formula> courses of antivirals). This implies that predispensing <inline-formula><tex-math id="d20e1774">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q-q_I\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; courses after predispensing the initial <inline-formula><tex-math id="d20e1779">\documentclass[10pt]{article}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{mathrsfs}
\usepackage{pmc}
\usepackage[Euler]{upgreek}
\pagestyle{empty}
\begin{document}
\begin{equation*}q_I\end{equation*}\end{document}</tex-math></inline-formula>&#x000a0; courses would be beneficial. </p></sec></sec></body><back><ref-list><ref id="ref-3070768605"><mixed-citation>Aoki FY, Macleod MD, Paggiaro P, Carewicz O, El Sawy A, Wat C,
      Griffiths M, Waalberg E, Ward P, IMPACT Study Group: Early administration of oral oseltamivir
      increases the benefits of influenza treatment. J Antimicrob. Chemother. 2003; 51(1) 123-9</mixed-citation></ref><ref id="ref-2509778060"><mixed-citation>Burch J, Corbett M, Stock C, Nicholson K, Elliot AJ, Duffy S, Westwood
      M, Palmer S, Stewart L: Prescription of anti-influenza drugs for healthy adults: a systematic
      review and meta-analysis. Lancet Infect Dis. 2009 Aug 7. [Epub ahead of print]<pub-id pub-id-type="pmid">19665930</pub-id></mixed-citation></ref><ref id="ref-2593680428"><mixed-citation>McClellan K, Perry CM, Oseltamivir: a review of its use in influenza.
      Drugs. 2001;61(2):263-83.</mixed-citation></ref><ref id="ref-2321005289"><mixed-citation>Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of
      oseltamivir treatment on influenza-related lower respiratory tract complications and
      hospitalizations. Arch Intern Med. 2003 Jul 28;163(14):1667-72.</mixed-citation></ref><ref id="ref-1556464731"><mixed-citation>Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, et al.
      Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009. N Engl J
      Med 2009 Oct 8.</mixed-citation></ref><ref id="ref-3562892496"><mixed-citation>Janice K. Louie; Meileen Acosta; Kathleen Winter; et al. Factors
      associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in
      California. JAMA. 2009;302(17):1896-1902 (doi:10.1001/jama.2009.1583)</mixed-citation></ref><ref id="ref-316639952"><mixed-citation>CNN. Oct. 13, 2009 Study: Underlying conditions playing less of role in
      H1N1 http://www.cnn.com/2009/HEALTH/10/13/h1n1.preexisting.conditions/index.html</mixed-citation></ref><ref id="ref-2436736239"><mixed-citation>Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL,
      Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA.
      Lancet. 2009 Aug 8;374(9688):451-8.</mixed-citation></ref><ref id="ref-1590500135"><mixed-citation>Ministerio de Salud, Chile. Influenza pandemica (H1N1) 2009. REPORTE 21
      DE OCTUBRE DE http://www.redsalud.gov.cl/minsalaudios/reporte22octubre.pdf</mixed-citation></ref><ref id="ref-1504385554"><mixed-citation>Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M,
      Quinones-Falconi F, Bautista E, et al. Pneumonia and respiratory failure from swine-origin
      influenza A (H1N1) in Mexico. N Engl J Med2009 Aug 13;361(7):680-9.</mixed-citation></ref><ref id="ref-1239612372"><mixed-citation>Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, et al.
      Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in
      Spain. Crit Care2009 Sep 11;13(5):R148</mixed-citation></ref><ref id="ref-166664201"><mixed-citation>H1N1 leading to increased flu rates, more pediatric deaths.
        http://www.rwjf.org/publichealth/digest.jsp?id=23828</mixed-citation></ref><ref id="ref-3139123044"><mixed-citation>CDC. Updated Interim Recommendations for the Use of Antiviral
      Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season.
        http://www.cdc.gov/h1n1flu/recommendations.htm</mixed-citation></ref><ref id="ref-3427677528"><mixed-citation>Public Health Agency of Canada. Use of antivirals to treat H1N1 flu
      virus. http://www.phac-aspc.gc.ca/alert-alerte/h1n1/antiviral-antiviraux05-01-eng.php</mixed-citation></ref><ref id="ref-776221430"><mixed-citation>Minist&#x000e8;re charg&#x000e9;e de la sant&#x000e9;. Prise en charge
      d&#x02019;un cas de grippe A( H1N1) chez un adulte ou un enfant de plus de 40 kg. Grippe,
      formation, information, communication. Fiche m&#x000e9;mo; 2009;
        http://www.sante-sports.gouv.fr/IMG//pdf/Prise_en_charge_d_un_cas_de_grippe_A_H1N1_chez_un_adulte_ou_un_enfant_de_plus_de_40_kg.pdf</mixed-citation></ref><ref id="ref-2030528610"><mixed-citation>Department of Health and Ageing, Australia. Antiviral medication use
      &#x02013; treatment.
        http://www.healthemergency.gov.au/internet/healthemergency/publishing.nsf/Content/clinical-antiviral</mixed-citation></ref><ref id="ref-2242979749"><mixed-citation>National Health Coordination Center, New Zealand. Guidance on the
      diagnosis and management of Pandemic (H1N1) 2009 in the Pandemic &#x02018;Management&#x02019;
      phase, Version 3.
        http://www.moh.govt.nz/moh.nsf/pagesmh/9171/$File/diagnosis-and-mgmt-guidance-for-mgmt-phase-v3-30july09.doc</mixed-citation></ref><ref id="ref-1110531368"><mixed-citation>MIDAS High Risk Segmentation Group. (D. Wagener, private communication,
        2009).</mixed-citation></ref><ref id="ref-3267758521"><mixed-citation>Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM.
      Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;
        295(13):1549-1555.</mixed-citation></ref><ref id="ref-2562081569"><mixed-citation>CDC. A weekly influenza surveillance report prepared by the influenza
      division. http://www.cdc.gov/flu/weekly/</mixed-citation></ref><ref id="ref-1047776214"><mixed-citation>Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular
      disease as a risk factor for respiratory failure in children hospitalized with influenza
      infection. JAMA 2005;294:2188-2194</mixed-citation></ref><ref id="ref-374826205"><mixed-citation>Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, Dutkowski R,
      Hoffmann G, Breidenbach A, Lindemann L, Carey E, Boak L, Gieschke R, Sacks S, Solsky J, Small
      I, Reddy D. Assessment of neuropsychiatric adverse events in influenza patients treated with
      oseltamivir: a comprehensive review. Drug Saf. 2008;31(12):1097-114. doi:
      10.2165/0002018-200831120-00006. Review.<pub-id pub-id-type="pmid">19026027</pub-id></mixed-citation></ref><ref id="ref-2583398228"><mixed-citation>Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance:
      a population perspective. Emerg Infect Dis. 2002 Apr;8(4):347-54.</mixed-citation></ref><ref id="ref-779459754"><mixed-citation>Weekly pandemic flu media update. Health Protection Agency. 22 October
      2009 http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1254510639308</mixed-citation></ref><ref id="ref-3773165249"><mixed-citation>Lipsitch M, Cohen T, Murray M, Levin BR (2007) Antiviral Resistance and
      the Control of Pandemic Influenza. PLoS Med 4(1): e15.
        http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0040015</mixed-citation></ref><ref id="ref-1040828799"><mixed-citation>Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S (2009) Hedging against
      Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an
      Alternative Chemotherapy. PLoS Med 6(5): e1000085.
        http://www.plosmedicine.org/article/info:doi%2F10.1371%2Fjournal.pmed.1000085</mixed-citation></ref><ref id="ref-3446914576"><mixed-citation>Presanis AM, Lipsitch M, DeAngelis D et. al. The severity of pandemic
      H1N1 influenza in the United States, April &#x02013; July 2009
        http://knol.google.com/k/anne-m-presanis/the-severity-of-pandemic-h1n1-influenza/agr0htar1u6r/16#</mixed-citation></ref><ref id="ref-3342172176"><mixed-citation>Washington Post. Oct 2, 2009. CDC Reports 28 Flu Deaths Among Pregnant
      Women. http://www.washingtonpost.com/wp-dyn/content/article/2009/10/01/AR2009100104308.html</mixed-citation></ref><ref id="ref-3911190679"><mixed-citation>Swine flu poses risks to kids with neurological conditions. Medline
      Plus, Sep. 3, 2009 http://www.nlm.nih.gov/medlineplus/news/fullstory_88952.html</mixed-citation></ref><ref id="ref-1200866011"><mixed-citation>E. Goldstein, M. Lipsitch. Antiviral usage for H1N1 treatment: pros,
      cons, and an argument for broader prescribing guidelines in the United States. PLOS Currents
      Influenza.
        http://knol.google.com/k/edward-goldstein/antiviral-usage-for-h1n1-treatment-pros/1dfgb8wq76hv/2#</mixed-citation></ref><ref id="ref-3893845834"><mixed-citation>Goldstein E, Cowling B, O&#x02019;Hagan J, Danon L, Fang V, Hagy A,
      Miller JC, Reshef D, Robins J, Biedrzycki P, Lipsitch M. Oseltamivir for treatment and
      prevention of pandemic influenza A/H1N1 virus infection in households, Milwaukee, 2009,
      Submitted. http://www.plosmedicine.org/article/info:doi%2F10.1371%2Fjournal.pmed.1000085</mixed-citation></ref></ref-list></back></article>